Quantcast
Last updated on April 18, 2014 at 15:19 EDT

Latest Galantamine Stories

2013-12-03 08:32:22

NEW YORK, Dec. 3, 2013 /PRNewswire/ -- Anavex Life Sciences Corp. ("Anavex" or the "Company") (OTCQB: AVXL) today announced the appointment of Michael Gold, MD, as a member of its Scientific Advisory Board. Dr. Gold has over 20 years of experience in the clinical development of Alzheimer's and other central nervous system (CNS) drugs and currently serves as Vice President of the CNS practice at UCB, Inc., a global biopharmaceutical company. His background also includes leadership...

Cognitive Enhancers Not Effect Against Cognitive Impairment
2013-09-17 08:41:15

redOrbit Staff & Wire Reports - Your Universe Online Memory and concentration-improving drugs do not improve cognition or brain function, and may actually cause adverse health effects in people with mild cognitive impairment, according to research in Monday’s edition of the Canadian Medical Association Journal. These medications, which are known as cognitive enhancers, were found to be ineffective in treating patients suffering from mild cognitive impairment, a condition marked by...

2013-05-08 17:12:26

Virginia Tech scientists bring clarity to how most Alzheimer's drugs sharpen brain performance Scientists at the Virginia Tech Carilion Research Institute have discovered how the predominant class of Alzheimer's pharmaceuticals might sharpen the brain's performance. One factor even more important than the size of a television screen is the quality of the signal it displays. Having a life-sized projection of Harry Potter dodging a Bludger in a Quidditch match is of little use if the...

2012-12-05 20:20:50

HOLLYWOOD, Fla., Dec. 5, 2012 /PRNewswire/ -- New study findings presented today showed a significantly lower mortality rate in patients who were treated with galantamine, a prescription medicine for mild to moderately severe Alzheimer's disease, versus those who received placebo. Patients treated with galantamine also had significantly lesser decline in cognitive impairment after two years, compared to patients in the placebo group, according to investigators presenting the data at the...

2011-01-18 14:30:12

A review of research evidence produced by researchers from the Peninsula Technology Assessment Group, part of the Peninsula College of Medicine and Dentistry, has played a pivotal role in the decision by the National Institute for Health and Clinical Excellence (NICE) to extend the availability of donepezil, galantamine, rivastigmine and memantine for Alzheimer's disease announced today (18th January 2011). A previous appraisal by NICE of these drugs in 2004 approved the use of donepezil,...

2009-10-02 10:41:57

New study finds that older people hospitalized for bradycardia are more likely to be taking cholinesterase-inhibiting drugs such as donepezil People taking one of several drugs commonly prescribed to treat Alzheimer's disease are more likely to be hospitalized for a potentially serious condition called bradycardia than patients not taking these medications. Researchers from St. Michael's Hospital and Ontario's Institute for Clinical Evaluative Sciences (ICES) analyzed data from 1.4 million...

2009-08-24 11:57:00

COLUMBUS, Ohio, Aug. 24 /PRNewswire/ -- Roxane Laboratories, Inc. announced today the availability of Galantamine Hyrdrobromide Oral Solution, 4mg/mL as of August 14, 2009. The product, indicated for mild to moderate dementia related to Alzheimer's disease, is available for immediate shipment to wholesalers and pharmacies nationwide. Currently this product is available as a generic from Roxane Laboratories. Roxane Laboratories' Galantamine Hydrobromide Oral Solution is AA rated to...

2008-12-16 07:00:00

CORONA, Calif., Dec. 16 /PRNewswire-FirstCall/ -- Watson Pharmaceuticals, Inc. (NYSE: WPI), a leading specialty pharmaceutical company, today announced that its subsidiary, Watson Laboratories, Inc., has received approval today from the United States Food and Drug Administration on its Abbreviated New Drug Application (ANDA) for galantamine hydrobromide extended-release capsules, eq. to 8 mg, 16 mg and 24 mg (galantamine base). Galantamine hydrobromide extended-release capsules are the...

2008-08-28 09:01:23

TITUSVILLE, N.J., Aug. 28 /PRNewswire/ -- Ortho-McNeil Neurologics, Division of Ortho-McNeil-Janssen Pharmaceuticals, Inc. announced that it will appeal yesterday's decision by the U.S. District Court of Delaware, which ruled the patent for RAZADYNE(R) (galantamine hydrobromide) is invalid. The decision allows FDA-approved generic versions of immediate-release galantamine hydrobromide to enter the U.S. marketplace "at risk" pending an appeal. A favorable ruling would have provided patent...

2008-08-01 06:00:46

Forest Laboratories has presented positive Phase III data of a once-daily extended-release formulation of Namenda for Alzheimer's disease. The study evaluated the efficacy, safety and tolerability of an innovative, proprietary, 28mg once-daily extended-release formulation of Namenda (memantine HCl) compared to placebo in outpatients with moderate to severe Alzheimer's disease already being treated with a cholinesterase inhibitor (donepezil, galantamine or rivastigmine). In the study,...